BRIEF—Pfizer expects to hike US COVID-19 vaccine price post emergency setting

US pharma giant Pfizer indicted it will increase the US price of its COVID-19 vaccine Comirnaty to about $110 to $130 per dose after the US government's current purchase program expires, the firm’s executive Angela Lukin said on Thursday, according to a report by Investing.com.

The US government currently pays around $30 per dose to Pfizer and German partner BioNTech, meaning an around four-fold hike in future.

In 2023, the market is expected to move to private insurance after the US public health emergency expires.

Commentary by Pfizer yesterday signaled meaningfully higher-than-expected pricing for its COVID-19 vaccine as the market shifts from a largely contracted to a largely commercial one, noted SVB Securities analyst Dr Mani Forhoohar.

Presuming that Moderna’s prices for its COVID-19 vaccine as a rational duopolist, this substantially improves the company’s ability to meet 2023 revenue guidance, he opined.